Dapirolizumab Pegol Phase 3 Data in SLE Presented at the Annual European Congress of Rheumatology (EULAR) Show Improvement in Fatigue and Reduction in Disease Activity Jun 12, 2025 01:00AM
Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity Nov 19, 2024 01:00AM
Amgen (AMGN) Confirms FDA Approves EVENITY For Treatment Of Osteoporosis in Postmenopausal Women Apr 9, 2019 03:59PM
FDA Approves EVENITY™ (romosozumab-aqqg) For The Treatment Of Osteoporosis In Postmenopausal Women At High Risk For Fracture Apr 9, 2019 03:57PM
Amgen (AMGN), UCB Confirm Positive Vote From FDA Panel in Favor of Approval for EVENITY (romosozumab) Jan 16, 2019 05:44PM


Jan 16, 2019 05:41PM Amgen And UCB Receive Positive Vote From FDA Advisory Committee In Favor Of Approval For EVENITY™ (romosozumab)